MaxCyte
MXCT
116 hedge funds and large institutions have $303M invested in MaxCyte in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 48 increasing their positions, 36 reducing their positions, and 10 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 36
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
2% more funds holding
Funds holding: 114 → 116 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.11% less ownership
Funds ownership: 64.27% → 64.16% (-0.11%)
38% less capital invested
Capital invested by funds: $489M → $303M (-$186M)
78% less call options, than puts
Call options by funds: $5K | Put options by funds: $23K
Top Buyers
Top Sellers
| 1 |
BAMCO Inc
New York
|
-$9.84M |
| 2 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
-$6.16M |
| 3 |
Millennium Management
New York
|
-$4.18M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$2.49M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$1.41M |
MXCT Hedge Fund Activity: Q2 2023 in Review
116 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in MaxCyte (MXCT) for Q2 2023, worth a combined $303M — down 38% from $489M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new MXCT positions and 10 closed out — a net gain of 2 holders — while 48 added to existing stakes and 36 trimmed.
The largest buyer was Stonepine Capital Management, adding an estimated $5.79M. The largest seller was BAMCO Inc, exiting entirely with an estimated $9.84M sold.
- 116 institutional investors held MaxCyte (MXCT) as of Q2 2023, up from 114 in Q1 2023.
- Funds reported $303M of MaxCyte stock for Q2 2023, down 38% quarter-over-quarter.
- 12 funds opened new MaxCyte positions in Q2 2023 and 10 closed out, a net change of +2 holders.
- The largest MaxCyte buyer in Q2 2023 was Stonepine Capital Management, an estimated $5.79M added.
- The largest MaxCyte seller in Q2 2023 was BAMCO Inc, an estimated $9.84M sold.
Based on aggregated 13F filings for Q2 2023.